TARGETED CELLULAR CYTOTOXICITY

已经建立了一种小鼠乳腺癌模型来测量这种能力。 靶向效应细胞用于根除原发和移植的乳腺 肿瘤。含有抗CD3的双特异性抗体与 抗小鼠乳腺肿瘤病毒gp52抗体结合 特异性地作用于自发或培养的乳腺肿瘤细胞，并诱导 体内皮下移植肿瘤。一种基因工程 已经在体外产生了具有相同特性的双特异性F(ab‘)2结构物 以常规制备的双特异性抗体为靶向活性。 单元格 介导这种定向裂解存在于LGL人群中，是CD56+，和 被IL-2激活。

A murine breast cancer model has been developed for measuring the ability of targeted effector cells to eradicate primary and transplanted mammary tumors. Bispecific antibodies containing anti-CD3 cross linked to antibodies against gp52 from the mouse mammary tumor virus bind specifically to spontaneous or cultured mammary tumor cells, and induce murine T cells to lyse such cells in vitro and block the growth of subcutaneous tumor transplants in vivo. A genetically engineered bispecific F(ab')2 construct has been produced that has the same in vitro targeting activity as conventionally prepared bispecific antibodies. By using anti-CD44 containing bispecific antibodies, we have found that CD44 is a cytotoxic triggering molecule on a subset of human PBL. Cells mediating such targeted lysis reside in the LGL population, are CD56+, and are activated by IL-2.